治疗前MR影像组学特征预测鼻咽癌诱导化疗早期反应
本研究回顾性纳入120例活检证实的II-IV期鼻咽癌患者,从治疗前形态学MR图像提取纹理特征,用LASSO logistic回归构建影像组学特征。增强T1WI选出5个特征,AUC为0.715;联合T1WI、T2WI、T2WI FS和增强T1WI选出15个特征,AUC为0.822,性能优于仅用增强T1WI(P<0.05)。结论认为治疗前形态学MR影像组学特征可预测诱导化疗早期反应。
要点
- 增强T1WI影像组学特征可区分诱导化疗反应与无反应组(P<0.001),AUC 0.715。
- 联合T1WI、T2WI、T2WI FS和增强T1WI的15特征模型AUC 0.822,优于仅增强T1WI模型(P<0.05)。
- 单独从T1WI、T2WI或T2WI FS图像未选出有价值特征。
核心结论
- 治疗前形态学MR影像组学特征可预测鼻咽癌患者诱导化疗的早期反应。
研究设计与样本
- 回顾性研究,纳入120例活检证实的II-IV期鼻咽癌患者,从治疗前形态学MR图像提取纹理特征,采用LASSO logistic回归模型构建影像组学特征。
诊断标准与关键数值
- 增强T1WI模型:LASSO选出5个特征,区分反应与无反应组P<0.001,AUC 0.715(95% CI 0.699-0.731),敏感度0.940,特异度0.500,阳性预测值0.568,阴性预测值0.897,以无反应者为真阳性;1000次bootstrap内部验证AUC 0.715。
- 联合T1WI、T2WI、T2WI FS和增强T1WI模型:选出15个特征,性能优于仅增强T1WI模型(P<0.05),AUC 0.822(95% CI 0.809-0.835),敏感度0.980,特异度0.529,阳性预测值0.593,阴性预测值0.949;1000次bootstrap分析AUC 0.821。
- 单独从T1WI、T2WI、T2WI FS图像未选出有价值特征。
临床应用与阅片要点
- 治疗前形态学MR影像组学特征可能有助于预测鼻咽癌诱导化疗早期反应。
- 联合多序列(T1WI、T2WI、T2WI FS、增强T1WI)的影像组学特征预测性能优于仅用增强T1WI。
- 以无反应者为真阳性时,增强T1WI模型阴性预测值0.897,联合模型阴性预测值0.949。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: This study aimed to investigate the capability of magnetic resonance (MR) imaging radiomics signatures for pretreatment prediction of early response to induction chemotherapy in patients with nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: This was a retrospective study consisting of 120 patients with biopsy-proven NPC (stage II-IV). Texture features were extracted from the pretreatment morphological MR images for each case. Radiomics signatures were obtained with the least absolute shrinkage and selection operator method (LASSO) logistic regression model. The association between the radiomics signatures and the early response to induction chemotherapy was explored.
RESULTS: From the contrast-enhanced T1-weighted MR imaging (CE T1WI), 5 features were selected by the LASSO model. The radiomics signature categorised patients with NPC into response and nonresponse groups (P<0.001). The area under the receiver operating characteristic curve values (AUC), sensitivity, specificity, positive predictive value (PPV) and negative predictive value(NPV) were 0.715(95% CI 0.699-0.731), 0.940, 0.500, 0.568 and 0.897 respectively, where non-responders are true-positives. The AUC of 1000 bootstrap internal validation was 0.715. Furthermore, when the features of T1-weighted MR imaging (T1WI), T2-weighted MR imaging (T2WI), T2-weighted fat-suppressed MR imaging (T2WI FS) and CE T1WI were analysed together, 15 features were selected to develop the radiomics signature. The performance of this radiomics signature was better than that developed only from CE T1WI (P<0.05). The AUC value was 0.822(95% CI 0.809-0.835) with sensitivity of 0.980, specificity of 0.529, PPV of 0.593 and NPV of 0.949. The AUC of 1000 bootstrap analysis was 0.821. From T1WI, T2WI, and T2WI FS images separately, no valuable features were selected.
CONCLUSIONS: Pretreatment morphological MR imaging radiomics signatures can predict early response to induction chemotherapy in patients with NPC.
引用
- Wang G, He L, Yuan C, et al. Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma. Eur J Radiol. 2017. PMID: 29279146. doi:10.1016/j.ejrad.2017.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。